Thrivent Financial For Lutherans Clovis Oncology, Inc. Transaction History

Thrivent Financial For Lutherans

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $257,245 - $399,259	-62,287 Closed	0 $0
Q3 2020 Nov 10, 2020	SELL	$4.82 - $7.72 $2,029 - $3,250	-421 Reduced 0.67%	62,287 $363,000
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $236,409 - $689,788	62,708 New	62,708 $399,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.